Clinical trial Recruiting at 1 site Interventional Ages 18 and up

RH210A hearing aid performance in adults with mild-to-moderate hearing loss

Official title: Clinical Evaluation of the RH210 Hearing Aid Software Used With RH210A Device in Adults With Perceived Mild-to-Moderate Hearing Loss

Run by Rehear Audiology Company LTD · NCT07572357 · Data updated 2026-11-12

This study tests whether the RH210A hearing aid improves understanding of speech in noisy settings for adults with mild-to-moderate sensorineural hearing loss.

More Sensorineural Hearing Loss trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment24 (estimated)
SponsorRehear Audiology Company LTD
Industry-sponsored
Locations1 site (Macquarie Park, New South Wales)
StatusRecruiting
StartedApril 11, 2026
Main results expectedJuly 30, 2026
Study endsAugust 30, 2026
Registry record updatedMay 29, 2026
Trial IDNCT07572357 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 and older with self-perceived mild-to-moderate hearing loss who can use a smartphone and complete self-fitting via an app.

Probably not a fit

Individuals with conductive or mixed hearing loss, active ear pathology, or profound loss may not benefit from this device.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional investigation evaluates the RH210A air-conduction hearing aid in adults who perceive mild-to-moderate hearing difficulty. The primary goal is to show a clinically meaningful improvement in speech understanding in noise when using RH210A versus unaided listening, measured with the BKB-SIN test. Participants will use the device alongside Apple AirPods Pro (2nd Gen) with Hearing Aid Features and complete two in-person visits. The key endpoint is the mean 2 dB or greater improvement in SNR with RH210A compared to unaided listening. Safety and device performance will be monitored throughout the study.

Why it matters

Potential benefit: If successful, users could achieve better speech understanding in noisy environments with the RH210A device.

How similar studies have gone: Previous research in similar OTC-style hearing aid approaches has shown variable but encouraging improvements in speech-in-noise performance.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years
* Self-perceived mild-to-moderate hearing difficulties/ hearing loss
* Competent smartphone use (able to complete self-fitting via the app)
* Able and willing to provide informed consent
* HHIA screening consistent with perceived hearing difficulty
* Willingness and ability to attend two in-person research appointments
* Ability to operate a SmartPhone

Exclusion Criteria:

* Conductive or mixed hearing loss
* Occluding cerumen
* Otologic disease/ active ear pathology
* Severe or profound hearing loss (PTA \>S0dBHL) (WHO, 2021)
* Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
* Visible deformity of the ear (congenital or traumatic).
* Fluid, pus, or blood coming from the ear (e.g., active drainage).
* Sudden or rapidly progressive hearing loss within the recent past (often defined as within \~90 days).
* Any acute or chronic dizziness or vertigo associated with hearing issues.
* Pain or discomfort in or around the ear.
* Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
* Unilateral hearing loss of sudden onset or large asymmetry between ears.
* Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
* Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
* Unilateral hearing loss of sudden onset or large asymmetry between ears

Where it's running

  • National Acoustic Laboratories
    Macquarie Park, New South Wales, Australia
    Recruiting

Study contacts

  • Principal investigator: Bettina Turnbull, Doctor of Audiology — National Acoustic Laboratories
  • Study coordinator: Marisa Poulos, Master of Audiology
  • Email: marisa.poulos@nal.gov.au
  • Phone: +61 2 9412 6872

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.